Genetically Engineered Phages: a Review of Advances over the Last Decade

dc.commentsCEB38960por
dc.contributor.authorPires, Diana P.por
dc.contributor.authorCleto, Sarapor
dc.contributor.authorSillankorva, Sannapor
dc.contributor.authorAzeredo, Joanapor
dc.contributor.authorLu, Timothy K.por
dc.date.accessioned2016-12-07T09:43:02Z
dc.date.available2016-12-07T09:43:02Z
dc.date.issued2016-09
dc.date.updated2016-12-02T00:25:46Z
dc.description.abstractSummary: Soon after their discovery in the early 20th century, bacteriophages were recognized to have great potential as antimicrobial agents, a potential that has yet to be fully realized. The nascent field of phage therapy was adversely affected by inadequately controlled trials and the discovery of antibiotics. Although the study of phages as anti-infective agents slowed, phages played an important role in the development of molecular biology. In recent years, the increase in multidrug-resistant bacteria has renewed interest in the use of phages as antimicrobial agents. With the wide array of possibilities offered by genetic engineering, these bacterial viruses are being modified to precisely control and detect bacteria and to serve as new sources of antibacterials. In applications that go beyond their antimicrobial activity, phages are also being developed as vehicles for drug delivery and vaccines, as well as for the assembly of new materials. This review highlights advances in techniques used to engineer phages for all of these purposes and discusses existing challenges and opportunities for future work.por
dc.description.sponsorshipD.P.P. acknowledges financial support from the Portuguese Foundation for Science and Technology (FCT) through grant SFRH/BD/76440/2011. This work was funded by The Center for Microbiome Informatics and Therapeutics and NSF Expeditions in Computing Program award #1522074 as part of the Living Computing Project. This work was further supported by grants from the Defense Threat Reduction Agency (grants HDTRA1-14-1-0007 and HDTRA1-15-1-0050), the National Institutes of Health (grants 1DP2OD008435,1P50GM098792,1R01EB017755, and 1R21AI12166901), and the U.S. Army Research Laboratory and U.S. Army Research Office, through the Institute for Soldier Nanotechnologies, under contract number W911NF-13-D-0001.S.S.is an FCT investigator (IF/01413/2013). D.P.P., S.S., and J.A. also acknowledge financial support from FCT under the scope of the strategic funding of the UID/ BIO/04469/2013 unit and COMPETE 2020 (grant POCI-01-0145FEDER-006684). T.K.L. is a founder of Sample6 Inc. and Eligo Biosciences, two companies developing phage-based technologies.por
dc.distributioninternationalpor
dc.identifier.citationPires, Diana P.; Cleto, Sara; Sillankorva, Sanna; Azeredo, Joana; Lu, Timothy K., Genetically Engineered Phages: a Review of Advances over the Last Decade. Microbiology and Molecular Biology Reviews, 80(3), 523-543, 2016por
dc.identifier.doi10.1128/MMBR.00069-15por
dc.identifier.issn1092-2172por
dc.identifier.pmid27250768por
dc.identifier.urihttps://hdl.handle.net/1822/43301
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherAmerican Society for Microbiology (ASM)por
dc.relationinfo:eu-repo/grantAgreement/FCT/SFRH/SFRH%2FBD%2F76440%2F2011/PTpor
dc.relationinfo:eu-repo/grantAgreement/FCT/5876/147337/PTpor
dc.relation.publisherversionhttp://mmbr.asm.org/por
dc.rightsopenAccesspor
dc.subject.wosScience & Technologypor
dc.titleGenetically Engineered Phages: a Review of Advances over the Last Decadepor
dc.typearticle
dspace.entity.typePublicationen
oaire.citationConferencePlaceUnited States
oaire.citationEndPage543por
oaire.citationIssue3por
oaire.citationStartPage523por
oaire.citationTitleMicrobiology and Molecular Biology Reviewspor
oaire.citationVolume80por
sdum.journalMicrobiology and Molecular Biology Reviewspor
sdum.publicationstatusinfo:eu-repo/semantics/publishedVersionpor

Ficheiros

Pacote original

A mostrar 1 - 1 de 1
A carregar...
Nome:
document_38960_1.pdf
Tamanho:
2.99 MB
Formato:
Adobe Portable Document Format